See the biopharma stock Goldman Sachs says to buy

Exclusively for CNBC Pro Subscribers - This stock is poised to rally nearly 40%

VIEW IN BROWSER | SUBSCRIBE MY ACCOUNT   Goldman Sachs says Buy This Stock   Goldman Sachs says Buy This Stock Morsa Images | DigitalVision | Getty Images Goldman Sachs says it's time for investors to put their money in this stock as its shares can rally nearly 40% with success trials of its new medicine.   Although shares for this company have rallied more than 320% since the release of the trial data, Goldman Sachs' analyst Corinne Jenkins sees further upside to the stock should this medicine continue to succeed in clinical trials.   Subscribe to CNBC Pro to see which stock Goldman Sachs says could rally and gain another 38% from Friday's close. See the Stock Here are more of today's top stories, exclusive for CNBC Pro subscribers!   Wall Street banks like growth stocks again. Here are the top picks from Goldman and more MON, AUGUST 08 2022   Most of Warren Buffett's equity portfolio is tied up in just 5 stocks. Here's what they are SAT, AUGUST 06 2022   Here are Monday's biggest analyst calls: Tesla, Amazon, First Solar, Roku, Apple, Carvana & more MON, AUGUST 08 2022   BlackRock says the era of steady growth has ended — and it tells investors how to position for it MON, AUGUST 08 2022   Goldman Sachs says buy this biopharma stock that's poised to rally nearly 40% from here MON, AUGUST 08 2022   An explanation of the 'pain trade' on Wall Street and why today it is stocks continuing to go higher MON, AUGUST 08 2022     Like getting these emails?  Subscribe to CNBC Pro today and get access to unlimited Pro articles, access to Pro live events, stock tips, and money-making investment ideas. Unsubscribe Digital Products Manage Newsletters Feedback Terms of Service Privacy Policy Join the CNBC Panel © 2022 CNBC LLC. All rights reserved. A property of NBCUniversal.   900 Sylvan Avenue, Englewood Cliffs, NJ 07632   Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes and Market Data and Analysis.   Data also provided by THOMSON REUTERS